• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    National Philanthropic Trust Welcomes Three Board Members

    1/3/24 9:30:00 AM ET
    $BANR
    $HLNE
    $OCGN
    Major Banks
    Finance
    Investment Managers
    Finance
    Get the next $BANR alert in real time by email

    Jeffrey Armbrister, Lindy Benton-Moreno, and Connie Collingsworth join the Board of Trustees at the largest national, independent donor-advised fund public charity

    National Philanthropic Trust (NPT), the largest national, independent public charity that manages donor-advised funds, and one of the leading grantmaking institutions in the U.S., is pleased to announce the appointment of Jeffrey Armbrister, Lindy Benton-Moreno, and Connie Collingsworth to its Board of Trustees.

    "As NPT continues to grow, innovate, and advance philanthropy around the world, we welcome these three accomplished professionals to our Board of Trustees," said Eileen Heisman, CEO of National Philanthropic Trust. "NPT is now the third largest grantmaking organization in the world. With esteemed careers in private market investing, technology, law, and philanthropy, Jeffrey Armbrister, Lindy Benton-Moreno, and Connie Collingsworth will make welcome additions to our board."

    Jeffrey Armbrister is an executive with more than 25 years of transaction-based investing and operational experience. He is the Chief Financial Officer of Hamilton Lane (NASDAQ:HLNE), a global private markets investment management firm.

    Armbrister previously served as the company's Global Head of Direct Equity Investments, where he was responsible for direction and oversight of the firm's direct equity and co-investment platform. His role included service on the boards of directors of companies in which Hamilton Lane invested on behalf of clients.

    Prior to joining Hamilton Lane, Armbrister served as Managing Director for Versa Capital Management, where he focused on making control-oriented, special situations, debt and equity investments in middle market companies across a variety of industries. While at Versa, he participated in all major investment functions, providing oversight for certain finance-related operational activities, including financial analysis and reporting and cash flow management for several portfolio companies.

    Prior to joining Versa, Armbrister was an Equity Research analyst at Oppenheimer + Close. He has also held private equity, venture capital, corporate development, and investment banking positions at Berwind Financial Group, Redleaf Group, ICG Commerce, and Wheat First Butcher Singer, respectively. He currently serves on the board of directors or similar bodies of several charitable organizations. Armbrister received his Bachelor of Arts in Economics from the University of Virginia.

    Lindy Benton-Moreno, an accomplished leader and sought-after speaker, has devoted her 30-year healthcare IT career to advancing technology and inspiring leaders. As an Executive Board Chair of Vyne, Benton-Moreno fueled the growth of a small dental company by establishing a thriving medical division.

    She was named by Health Data Management among the "Most Powerful Women in Healthcare IT" and recognized on Becker's "Women Power Players Health IT" list. As a Fellow at the Health Information and Management Systems Society, she engages with executive councils across health-related committees and industry associations.

    With a Master of Science from Florida State University, Benton-Moreno became a Distinguished Alumnus in Business and Industry, serving on the university's National Board of Directors as the university Alumni Association's National Director. Prior to entering healthcare IT, she pioneered the mainstreaming of 100+ children with disabilities into Florida's public schools and the sponsoring of scholarships for first-generation college students, an initiative close to her heart.

    Connie Collingsworth is an experienced board member with expertise in governance, risk management, executive compensation, and complex investments for publicly traded companies, private companies, and private equity funds. Her board experience includes leadership positions on public and private company boards as well as charitable organizations.

    Collingsworth's current board roles include Banner Corporation (NASDAQ:BANR) and Axxes Capital. She also serves as a Board Advisor to European private equity fund Planet First Partners, a Business Advisory Board Member to biotech company Ocugen (NASDAQ:OCGN), and a Strategic Advisor to venture fund LoudCapital.

    Collingsworth is the former Chief Operating Officer of the Bill & Melinda Gates Foundation, the largest private foundation in the world with over $65 billion in assets, distributing over $8.3 billion annually. During her 22-year tenure, she was responsible for managing and scaling the foundation's business operations globally. She also served as Chief Legal Officer, advising Bill Gates, Melinda French Gates, and Warren Buffett on governance, including creating the foundation's Governing Board. She was the architect of the foundation's IP philosophy and led the foundation's work in collaborating with for-profit companies, including big pharma and companies in the biotech and ed-tech sectors.

    Collingsworth holds a Master of Laws in International Business Studies from the University of Exeter, England, a Juris Doctorate from the University of Nebraska, and a Bachelor of Arts from Andrews University.

    About National Philanthropic Trust

    Founded in 1996, National Philanthropic Trust (NPT) is the largest national, independent public charity that manages donor-advised funds and one of the leading grantmaking institutions in the U.S. Since its founding, NPT has raised more than $49.8 billion in charitable funding and has made more than 640,000 grants exceeding $25.7 billion to nonprofits around the world. NPT annually publishes the Donor-Advised Fund Report, the sector's authority on the state of DAF philanthropy. Visit NPT's resource library to learn what you can do with a DAF and about NPT's impact investing options. More at NPTrust.org and NPTGivingPoint.org.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240103652385/en/

    Get the next $BANR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BANR
    $HLNE
    $OCGN

    CompanyDatePrice TargetRatingAnalyst
    Ocugen Inc.
    $OCGN
    3/17/2026$12.00Buy
    Canaccord Genuity
    Ocugen Inc.
    $OCGN
    3/11/2026$10.00Outperform
    Oppenheimer
    Hamilton Lane Incorporated
    $HLNE
    12/11/2025$166.00Buy
    UBS
    Hamilton Lane Incorporated
    $HLNE
    11/6/2025$165.00Neutral → Buy
    Goldman
    Hamilton Lane Incorporated
    $HLNE
    10/14/2025$181.00Perform → Outperform
    Oppenheimer
    Hamilton Lane Incorporated
    $HLNE
    10/13/2025$150.00Mkt Perform → Outperform
    Keefe Bruyette
    Hamilton Lane Incorporated
    $HLNE
    10/3/2025$150.00Outperform
    BMO Capital Markets
    Hamilton Lane Incorporated
    $HLNE
    9/18/2025$162.00Sell → Neutral
    Goldman
    More analyst ratings

    $BANR
    $HLNE
    $OCGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider O'Reilly Monica Bernadette

    3 - BANNER CORP (0000946673) (Issuer)

    3/24/26 12:37:28 PM ET
    $BANR
    Major Banks
    Finance

    SEC Form 3 filed by new insider Steiner Judith A

    3 - BANNER CORP (0000946673) (Issuer)

    3/24/26 12:34:06 PM ET
    $BANR
    Major Banks
    Finance

    Chief Operating Officer Kramer Andrea Anigati covered exercise/tax liability with 1,212 shares, decreasing direct ownership by 2% to 64,549 units (SEC Form 4)

    4 - Hamilton Lane INC (0001433642) (Issuer)

    3/17/26 7:02:56 PM ET
    $HLNE
    Investment Managers
    Finance

    $BANR
    $HLNE
    $OCGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Berkman David J bought $1,010,000 worth of shares (10,000 units at $101.00) (SEC Form 4)

    4 - Hamilton Lane INC (0001433642) (Issuer)

    2/25/26 4:06:57 PM ET
    $HLNE
    Investment Managers
    Finance

    Co-Chief Executive Officer Hirsch Erik R. bought $988,260 worth of shares (9,225 units at $107.13), increasing direct ownership by 15% to 70,494 units (SEC Form 4)

    4 - Hamilton Lane INC (0001433642) (Issuer)

    2/24/26 4:07:41 PM ET
    $HLNE
    Investment Managers
    Finance

    Co-Chief Executive Officer Delgado-Moreira Juan bought $989,311 worth of shares (9,225 units at $107.24), increasing direct ownership by 0.69% to 1,338,047 units (SEC Form 4)

    4 - Hamilton Lane INC (0001433642) (Issuer)

    2/24/26 4:07:12 PM ET
    $HLNE
    Investment Managers
    Finance

    $BANR
    $HLNE
    $OCGN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Ocugen Inc.

    SCHEDULE 13G/A - Ocugen, Inc. (0001372299) (Subject)

    3/27/26 11:04:08 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Hamilton Lane Incorporated

    SCHEDULE 13G/A - Hamilton Lane INC (0001433642) (Subject)

    3/27/26 9:32:12 AM ET
    $HLNE
    Investment Managers
    Finance

    Ocugen Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Ocugen, Inc. (0001372299) (Filer)

    3/26/26 7:13:22 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BANR
    $HLNE
    $OCGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Krug Promoted to Executive Vice President and Enterprise Operations Executive

    The Banner Bank leadership team announces the promotion of Jennifer Krug to Executive Vice President and Enterprise Operations Executive. In this role, Krug will continue leading the Bank's enterprise operations, supporting strong execution, operational excellence, and scalable infrastructure aligned with Banner's long-term strategic objectives. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326833118/en/Jennifer Krug, Executive Vice President of Enterprise Operations, Banner Bank "Elevating Jennifer to an executive-level leader recognizes her strategic vision, operational discipline and focus on execution that have strengthe

    3/26/26 7:52:00 PM ET
    $BANR
    Major Banks
    Finance

    Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

    Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (p< 0.05)Potential 2X treatment benefit compared to 15% and 22% reductions reported for currently approved therapies at 12 and 24 months, respectivelyNo serious adverse events and no adverse events of special interest related to OCU410 reported to date MALVERN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced positive 12-month data from the Phase 2 ArMaDa clinical trial evaluating OCU410 (AAV5-RORA), its novel modifier gene

    3/24/26 7:45:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Hamilton Lane Announces SEC Effectiveness for Firm's First Interval Fund

    The Hamilton Lane Credit Income Fund offers access to a diversified portfolio of middle-market senior loans sourced through Hamilton Lane's global multi-manager platform.CONSHOHOCKEN, Pa., March 24, 2026 /PRNewswire/ -- Leading global private markets firm Hamilton Lane (NASDAQ:HLNE) today announced that the Hamilton Lane Credit Income Fund ("HLCIF" or the "Fund") has been declared effective by the U.S. Securities and Exchange Commission. HLCIF is designed to deliver accessible entry points for wealth professionals across the experience spectrum, with investor-friendly features including 1099 tax reporting, quarterly limited liquidity and competitive fees. Structured as an interval fund and r

    3/24/26 7:00:00 AM ET
    $HLNE
    Investment Managers
    Finance

    $BANR
    $HLNE
    $OCGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Ocugen with a new price target

    Canaccord Genuity initiated coverage of Ocugen with a rating of Buy and set a new price target of $12.00

    3/17/26 8:33:47 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Oppenheimer initiated coverage on Ocugen with a new price target

    Oppenheimer initiated coverage of Ocugen with a rating of Outperform and set a new price target of $10.00

    3/11/26 8:39:19 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UBS resumed coverage on Hamilton Lane with a new price target

    UBS resumed coverage of Hamilton Lane with a rating of Buy and set a new price target of $166.00

    12/11/25 9:09:19 AM ET
    $HLNE
    Investment Managers
    Finance

    $BANR
    $HLNE
    $OCGN
    Financials

    Live finance-specific insights

    View All

    Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy

    MALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast with key opinion leaders (KOLs) and Ocugen executive leadership to discuss the full data set from the Phase 2 ArMaDa clinical trial evaluating OCU410 for geographic atrophy (GA), late-stage dry age-related macular degeneration (dAMD) at 8 a.m. EDT on Tuesday, March 24, 2026. KOLs leading the webcast include: Lejla Vajzovic, MD, FASRS, Professor of Ophthalmology, Director of CME-Ophthalmology, Duke University School of Medicine & Chairman, Ocu

    3/23/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Hamilton Lane Announces Strategic Investment in Republic

    CONSHOHOCKEN, Pa. and NEW YORK, March 17, 2026 /PRNewswire/ -- Hamilton Lane (NASDAQ:HLNE), a leading global private markets investment firm, today announced a strategic investment in Republic, a leading on-chain global investment platform, reinforcing the firms' shared commitment to expanding retail investor access to institutional-quality private market funds. The investment builds on the existing partnership between Hamilton Lane and Republic, and underscores Hamilton Lane's long-term strategy to modernize and expand access to private markets. Together, the firms are enabling broader participation in the private markets asset class, which has historically been limited to institutions and

    3/17/26 7:00:00 AM ET
    $HLNE
    Investment Managers
    Finance

    Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results

    MALVERN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's fourth quarter and full year 2025 financial results and provide a business update at 8:30 a.m. ET on Wednesday, March 4, 2026. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 3029428Webcast: Available on the events sec

    2/18/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BANR
    $HLNE
    $OCGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Hamilton Lane Incorporated

    SC 13G/A - Hamilton Lane INC (0001433642) (Subject)

    11/13/24 9:56:40 PM ET
    $HLNE
    Investment Managers
    Finance

    Amendment: SEC Form SC 13G/A filed by Ocugen Inc.

    SC 13G/A - Ocugen, Inc. (0001372299) (Subject)

    11/12/24 4:59:47 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Hamilton Lane Incorporated

    SC 13G/A - Hamilton Lane INC (0001433642) (Subject)

    11/12/24 3:55:46 PM ET
    $HLNE
    Investment Managers
    Finance

    $BANR
    $HLNE
    $OCGN
    Leadership Updates

    Live Leadership Updates

    View All

    Leading asset managers to join new Corastone platform as investors alongside Apollo, Franklin Templeton and KKR

    Expanded institutional participation underscores growing demand for private market opportunities and standardized operating infrastructureNEW YORK, March 9, 2026 /PRNewswire/ -- Corastone, the hyperscaler for private-market investing, today announced Fidelity Investments, Future Standard, and Hamilton Lane (NASDAQ:HLNE) as investors in Corastone and its alternative-investing operating platform. This growing institutional participation builds on Corastone's recent platform launch and comes as demand for private markets investments expands across investor types. As global private

    3/9/26 9:05:00 AM ET
    $HLNE
    Investment Managers
    Finance

    Hamilton Lane Expands Presence in Japan, Appointing Mika Tashiro as Head of Private Wealth for the Country

    Appointment underscores firm's commitment to expanding access to private markets for individual investors in JapanTOKYO, March 1, 2026 /PRNewswire/ -- Hamilton Lane (NASDAQ:HLNE), a leading global private markets investment firm, announced the appointment of Mika Tashiro as Head of Private Wealth Solutions in Japan. In this newly-created role, Tashiro will be responsible for leading Hamilton Lane's private wealth strategy in the country, deepening relationships with leading wealth management firms and financial institutions and expanding access to the firm's global evergreen platform for Japanese investors. In her role, Tashiro is focused on expanding Hamilton Lane's footprint across Japan's

    3/1/26 5:00:00 PM ET
    $HLNE
    Investment Managers
    Finance

    Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

    MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita Johnson-Greene as Chief Financial Officer (CFO). "Mrs. Johnson-Greene's diverse background across a variety of strategic roles at organizations representing many facets of the industry make her well-suited to serve as Ocugen's CFO," said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. "We look forward to her leadership as we enter into a transformative time at Ocugen, beginning with the submission of the first of three Biologics License Applications (BLAs) this

    2/9/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care